Ardent Health, Inc.
No SEC Form 4 filings for $ARDT in the last 30 days.
See all $ARDT insider activity →Ardent Health (ARDT) reclassified the departure of CEO Martin J. Bonick as termination for cause, citing failure to disclose third-party compensation. The board's decision, made Oct. 19, 2026, ends Bonick's severance benefits, including $4.5M in cash and unvested PRSUs, effective June 2, 2026.
Ardent Health, Inc. (ARDT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously disclosed, Martin J. Bonick’s employment as President and Chief Executive Officer of Ardent Health, Inc. (th
BMO Capital initiated coverage on Ardent Health Partners (NYSE:ARDT) with a Market Perform rating and a $11.00 price target. The company's stock trades at $10.95, near the analyst consensus. Ardent reported Q2 2026 adjusted earnings of $0.12 per share, missing estimates but showing strong revenue and cash flow. RBC and Guggenheim raised their price targets to $13.00 and $14.00, respectively, citing strong EBITDA and program benefits.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning ARDT (Ardent Health, Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 2 bearish.
Recent ARDT coverage spans corporate actions, financial news and earnings.
Negative executive departure likely triggers short-term sell pressure.
The termination for cause and loss of severance may weigh on the stock, suggesting governance concerns and potential litigation risk.
Analyst initiation may prompt short‑term buying interest and price support around the $11 target.
The call frames margin expansion and capacity management as controllable levers, with a quantified EBITDA uplift from a payer renewal.
Q2 showed revenue and Adjusted EBITDA declines, but operating cash flow rose sharply and guidance was reaffirmed, implying management expects volume and cost actions to offset headwinds.
AlphAI scores every news story that mentions ARDT with an AI model for sentiment and relevance, and aggregates insider trades from Ardent Health, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Ardent Health (ARDT) reclassified the departure of CEO Martin J. Bonick as termination for cause, citing failure to disclose third-party compensation. The board's decision, made Oct. 19, 2026, ends Bonick's severance benefits, including $4.5M in cash and unvested PRSUs, effective June 2, 2026.
1 min readArdent Health, Inc. (ARDT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously disclosed, Martin J. Bonick’s employment as President and Chief Executive Officer of Ardent Health, Inc. (th
1 min readBMO Capital initiated coverage on Ardent Health Partners (NYSE:ARDT) with a Market Perform rating and a $11.00 price target. The company's stock trades at $10.95, near the analyst consensus. Ardent reported Q2 2026 adjusted earnings of $0.12 per share, missing estimates but showing strong revenue and cash flow. RBC and Guggenheim raised their price targets to $13.00 and $14.00, respectively, citing strong EBITDA and program benefits.
2 min readArdent Health (ARDT) discussed its Q2 2026 earnings call, citing operational cost reductions under its IMPACT program, including a 42% contract labor spend cut and 0.7% year-over-year SWB growth. It expects 2026 savings to rise to over $70 million and raised adjusted EBITDA outlook by $5 million to $10 million from a June payer renewal. Virtual care via hellocare.ai reported 58% discharge completion in Texas and Idaho.
7 min readArdent Health, Inc. (ARDT) filed an SEC Form 8-K — Results of Operations and Financial Condition. 1 Exhibit 99.1 Ardent Health Reports Second Quarter 2026 Results Brentwood, Tenn. ( August 4, 2026 ) – Ardent Health, Inc. (NYSE: ARDT) ("Ardent Health" or the "Company"), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced res
6 min readArdent Health, Inc. (ARDT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ex101-separationrelease.htm EX-10.1 EX10.1 - Separation, Release 4930-6561-1447v.1 EXHIBIT 10.1 SEPARATION AGREEMENT AND GENERAL RELEASE This Separation Agreement and General Release (this “Agreement”) dated as of June 26, 2026, is entered into by and between AHS Manage
4 min readDeMichiei Robert purchased 11,260 shares of Ardent Health, Inc. (ARDT) at $8.73 on 2026-06-05.
1 min readLUMSDAINE ALFRED (Chief Financial Officer) purchased 10,000 shares of Ardent Health, Inc. (ARDT) at $8.81 on 2026-06-05.
1 min readArdent Health, Inc. reported its first-quarter 2026 results, showing a 7.0% increase in total revenue year-over-year to $1.60 billion and a 26.3% rise in Adjusted EBITDA to $124 million. Despite a slight decrease in admissions due to severe weather and a lighter respiratory season, the company reaffirmed its full-year 2026 financial guidance. The strong performance was attributed to disciplined execution, effective cost management, and the positive impact of its IMPACT program.
3 min readFaruqi & Faruqi, LLP is reminding investors of Ardent Health (ARDT) that the deadline to seek lead plaintiff status in a federal securities class action lawsuit is March 9, 2026. The lawsuit alleges that Ardent Health and its executives made misleading statements and failed to disclose information regarding the company's accounts receivable. This follows a significant drop in Ardent's stock price after the company announced a $43 million reduction in revenue due to accounting changes and a $54 million increase in professional liability reserves in Q3 2025.
4 min read
